MorphoSys, Heptares enter pact to develop antibody therapeutics targeting ... pharmabiz.com We believe that by combining Heptares' unique StaR platform for generating stable GPCRs as antigens with our antibody discovery technology, we will be able to unlock the immense potential of therapeutic antibodies against GPCRs." Malcolm Weir, chief ... |
